Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government steering committee for therapeutic clinical trials and other research (CAPNET).
In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. The “National Priority Research” designation, granted by CAPNET on the basis of assessment conducted by the REACTing Scientific Council, facilitates accelerated enrollment of patients in clinical trials, the activation of fast-track reviews and approval processes conducted by the French regulatory authorities (ANSM) and the French Ethics Committee (CPP), and better valuing of research centers’ active contribution.
Inotrem’s Phase IIa clinical trial, which takes place in France, Belgium and the United States will determine the safety, tolerability and potential signals of efficacy of nangibotide, the company’s lead product, in critically ill COVID-19 patients. This Phase IIa trial follows a preliminary study conducted by Prof. Sébastien Gibot at the CHRU of Nancy, which showed that the TREM-1 pathway was activated in critically ill COVID-19 patients and associated with outcome. TREM-1 is an immunomodulatory receptor expressed on innate immune and endothelial cells which amplifies and maintains inflammation. Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021.
Jean-Jacques Garaud, CEO of Inotrem, indicates: “This Research National Priority designation is an endorsement of both the work we have accomplished so far in fighting the COVID-19 pandemic and of the high potential of our lead product, nangibotide, for treating patients in ICU suffering from severe forms of COVID-19. Thanks to the strong commitment of regulatory bodies and the funding provided by Bpifrance, France’s public investment bank, we were able with our partners, CHRU of Nancy and CHU of Limoges, to launch this study in a timely manner. This governmental designation will allow us to accelerate this study and more rapidly assess the therapeutic potential for patients suffering from severe forms of COVID-19.”
Prof. Sébastien Gibot, lead study investigator, adds: “We are very pleased with this decision which will allow us to accelerate patients’ enrollment in France; we plan on enrolling a total of 60 patients. Results of the study are expected early Q2 2021 and will determine the safety, tolerability and potential signals of efficacy of nangibotide in COVID-19 patients. Previous clinical studies have demonstrated nangibotide’s safety and tolerability in patients suffering from septic shock, which is also characterized by acute inflammatory syndromes.”
In parallel, Inotrem is currently conducting a Phase IIb trial (ASTONISH) to treat septic shock patients with nangibotide in six European countries and in the United States. Previous clinical studies with nangibotide in septic shock demonstrated that it was safe, well tolerated and showed signals towards clinically relevant efficacy. Pre-clinical models have shown that nangibotide modulates the amplification of the immune response caused by the activation of TREM-1 and is able to restore appropriate inflammatory response and vascular function, resulting in improved survival in septic shock models.
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
About TREM-1 pathway
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock.
Media contact for Inotrem
Strategies & Image (S&I)
+33 6 03 35 92 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mano Būstas Partners with Airship to Power Proactive, Anticipatory Communications with Customers21.1.2021 11:00:00 EET | Press release
Customer engagement company Airship and City Service, one of the largest corporate groups engaged in facility and property management and integrated utility services in Europe, today unveiled a new partnership that will streamline communications between its Lithuanian property management company, Mano Būstas and its hundreds of customers across the region. Beginning in January, Airship’s Customer Engagement Platform will enable Mano Būstas to automate communication with customers across in-app messaging, push notifications, email, and SMS, offering a better customer service experience by proactively answering common questions throughout all stages of the customer lifecycle. City Service is offering the new services to Mano Būstas clients at a first stage, with plans to roll out the cooperation to other businesses and countries later in the year. This collaboration is part of City Service’s strategic direction towards digitalising and automating their full business processes in order to
Kinetic Vision Improves PCB Workflow by 500% with Altium 36521.1.2021 10:30:00 EET | Press release
A long-term change in the way that the various stakeholders in the electronics industry work together is taking place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210120005796/en/ In Altium Designer, Kinetic Vision found a PCB design solution for all of their projects that best supports the production of smart products that incorporate electronics, circuit boards and communications chipsets. (Photo: Altium LLC) Whether working from home, office or traveling for business, the need to work from anywhere in the world without being tethered to your desktop is here to stay. Altium is paving the way for engineers and designers to work from anywhere, and connect with anyone by making the Altium Designer user experience more collaborative and more readily available than ever before. Altium customer Kinetic Vision, a Cincinnati-based design, engineering, and development firm, is an innovator’s one-stop-shop for transforming even t
Temenos Hits Milestone of 60 Challenger Bank Clients, Confirming Status as Technology Provider of Choice21.1.2021 10:30:00 EET | Press release
Temenos (SIX: TEMN), the banking software company, announced that it has exceeded 60 challenger bank clients confirming its status as the technology provider of choice for this growing segment. With the rich functionality of Temenos’ integrated front-to-back SaaS offering, challenger banks can launch rapidly, scale fast, provide differentiated services to customers and grow profitably. A raft of digital banks – such as Alba, Alpian, Banco del Sol, Flowe, FlowBank, Lunar, Next Commercial Bank, Pepper, Varo Bank and WeLab Bank – have selected Temenos’ cloud-native, cloud-agnostic technology, joining the 3000+ Temenos customers around the globe including 41 out of the top 50 banks that run Temenos. News of Temenos exceeding the 60-bank milestone comes as the company launches new functionality designed specifically to cater to this fast-growing segment. Temenos Infinity helps challengers deliver frictionless onboarding experiences for SMEs, while offering robust protection from fraud with
Shin-Etsu Chemical Develops Silicone Thermal Interface Materials for Applications in Electric Vehicles and Hybrid Electric Vehicles21.1.2021 09:00:00 EET | Press release
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo, President: Yasuhiko Saitoh) has developed innovative silicone thermal interface materials for applications in electric vehicles (EV) and hybrid electric vehicles (HEV). With the electrification of automobiles, the demand for heat dissipation measures for lithium-ion batteries and for various other electronic control systems are increasingly becoming more sophisticated and diversified. With the accelerating worldwide growth in vehicle electrification, the amount of thermal interface materials in automotive parts has increased and their applications are expanding. In response to this changing market environment, Shin-Etsu Chemical has developed two kinds of new products with unique characteristics: 1) The “TC-PEN Series,” which features a distinctly reduced density, soft thermal interface pad that can meet the demand for a high level for EV and HEV applications, 2) The “TC-SET Series,” which features a high thermal interface soft pad with
Verimatrix Releases Advanced Code Protection Service for Android Application Bundles20.1.2021 19:45:00 EET | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced general availability of version 2.2 of the Verimatrix Application Protection service for Android. The company’s latest Code Protection service for Android applications now supports the forthcoming Android ecosystem change that will mandate the use of Android Application Bundles (AABs) in the second half of 2021. A significant shift for developers, the upcoming AAB mandate creates a need for simple, reliable software security that prevents app attacks. In addition to traditional APKs, the Verimatrix Application Protection service now also supports AABs defined by Google Play’s publishing guidelines. Other new features and in enhancements in Verimatrix Application Protection service for Android include: AAB support through the Verimatrix App Shield service or on-premise tool Upgraded whole app integrity verification based on certificate binding for pu
LG CHEM TO SEEK INNOVATIVE IDEAS FOR SUSTAINABLE TECHNOLOGIES WORLDWIDE THROUGH 3rd GLOBAL INNOVATION CONTEST20.1.2021 17:00:00 EET | Press release
LG Chem (KRX: 051910) announced on 20th January that it will host the 3rd Global Innovation Contest (GIC) for leading universities and research institutions worldwide. Being the first of its kind in the Korean chemical industry, Global Innovation Contest invites organizations around the world to discover innovative ideas for sustainable technologies. The contest is open for entry from 25th January to 31st March in 4 categories: Energy, Sustainability, Advanced Materials, and Digital Transformation (DX). Under the new vision of the company “We connect science to life for a better future,” Sustainability and DX are 2 categories newly added this year. All scholars and researchers interested in developing the next generation’s innovative technology and industry-academia collaboration research are welcome to participate and submit their research proposals through the official GIC website. (www.rnd.lgchem.com/global/gic) LG Chem will form a judging panel of internal experts to evaluate the r
H.I.G. Capital Sells RGIB's Bathroom Furniture Division to Roca20.1.2021 16:20:00 EET | Press release
H.I.G. Capital, ("H.I.G."), a leading global private equity investment firm with over €35 billion of equity capital under management, and the Royo family have entered into an agreement to sell the bathroom furniture division of RG International Bathroom (“RGIB or the “Company”) to Roca Sanitario, S.A. The Royo family will retain a minority stake in the division. Both H.I.G. and the Royo family will continue as shareholders of the shower tray business of RGIB, operating under the Fiora brand. H.I.G. partnered with the Royo family in December 2016 and has achieved a number of important milestones, including: Developing a new factory and brand in Poland (Maximus) that contributed to strengthening the leading position that RGIB already had in the Polish market under the Elita brand Entering new segments, channels and countries; one of the most relevant achievements was the entry into the DIY channel in Germany where RGIB is now a leading player Consolidating RGIB’s leading position in Spai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom